These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27469903)

  • 1. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma.
    Rood JJM; van Bussel MTJ; Schellens JHM; Beijnen JH; Sparidans RW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Sep; 1031():80-85. PubMed ID: 27469903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
    Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
    J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma.
    Zheng X; Wang W; Zhang Y; Ma Y; Zhao H; Hu P; Jiang J
    Biomed Chromatogr; 2018 Dec; 32(12):e4365. PubMed ID: 30119142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum.
    Müller C; Fietz C; Koehler P; Sibley G; Nforbugwe ACA; Streichert T; Wiesen MHJ
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Rapid and Sensitive LC-MS/MS Method for the Pharmacokinetic Study of Osimertinib in Rats.
    Xiong S; Deng Z; Sun P; Mu Y; Xue M
    J AOAC Int; 2017 Nov; 100(6):1771-1775. PubMed ID: 28534470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
    Sparidans RW; Martens I; Valkenburg-van Iersel LB; den Hartigh J; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1851-6. PubMed ID: 21622034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
    Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
    Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
    Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
    Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
    Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
    Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
    Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
    Aghai-Trommeschlaeger F; Zimmermann S; Gesierich A; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Kurlbaum M; Klinker H; Isberner N; Scherf-Clavel O
    Clin Biochem; 2022; 105-106():35-43. PubMed ID: 35483452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
    Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
    Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
    Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study.
    Cui X; Wang S; Gao H; Li B; Shi Y; Guo H; Song T; Zheng X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122488. PubMed ID: 33360679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
    Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
    Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma.
    Musijowski J; Filist M; Rudzki PJ
    Acta Pol Pharm; 2014; 71(6):1029-36. PubMed ID: 25745775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
    Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.